key: cord-1008641-l14m6g1x
authors: Dublin, S; Walker, R; Floyd, J S; Shortreed, S M; Fuller, S; Albertson-Junkans, L; Harrington, L B; Greenwood-Hickman, M A; Green, B B; Psaty, B M
title: Response to “ACE-2 downregulation and incidence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection”
date: 2020-12-15
journal: Am J Hypertens
DOI: 10.1093/ajh/hpaa212
sha: b329915319399434fef78beb83c75cde5ffaa4eb
doc_id: 1008641
cord_uid: l14m6g1x

nan

They propose that inhibiting ACE-2, the receptor by which SARS-CoV-2 enters cells, might be beneficial in preventing infection or severe outcomes and ask whether we could examine the association between use of aliskiren, a direct renin antagonist thought to downregulate ACE-2, and risk of SARS-CoV-2 infection or severe disease. We looked at our data and found that in the population we studied, aliskiren use was so rare that we would not have adequate power to examine this question. In the past year, patients in our healthcare system were dispensed fewer than 30 prescription fills for aliskiren. For comparison, there were about 150,000 medication dispensings for lisinopril, the most commonly used ACEI.

The idea that downregulation of ACE-2 could protect against SARS-CoV-2 infection or severe disease is intriguing and warrants further exploration. We would be interested to know if there are other, more commonly used medications that downregulate ACE-2 that could be the subject of future research.

Renin-angiotensinaldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study

M a n u s c r i p t